Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

seekingalpha.com - Bret Jensen - Ascendis Pharma Stock: Behind The Stock Surge (NASDAQ:ASND)
Ascendis Pharma Stock: Behind The Stock Surge (NASDAQ:ASND)
Seeking Alpha

Ascendis Pharma has more than tripled over the past two and a half years, driven by Yorvipath's blockbuster launch and Yuviwel's FDA approval. Yorvipath's rapid adoption and ongoing label expansion underpin robust revenue growth. Yuviwel-Skytrofa…

politifact.com - Caleb McCullough - No, Rogers didn't take $14M as 'pharma lobbyist'
No, Rogers didn't take $14M as 'pharma lobbyist'
PolitiFact

Michigan U.S. Senate candidate Abdul El-Sayed has centered healthcare in his campaign, championing Medicare for All and critiquing his opponents, both Democratic and Republican, on the issue. El-Sayed, a Democrat and former public health official…

digiday.com - Ronan Shields - The rise of pharma ad tech
The rise of pharma ad tech
Digiday - The home of modern media and marketing

Given the risks to patient safety, subsequent litigation risk, government oversight or overall reputational risk, the risk-averse orthodoxy among marketing practitioners in the sector is well understood. However, with the shifting sands at the Food…

fool.com - Prosper Junior Bakiny - Pfizer's CEO Says His Company Has a 'Very Big Balance Sheet' to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant
Pfizer's CEO Says His Company Has a 'Very Big Balance Sheet' to Do Deals. Here's the Perfect Next Acquisition Target for the Pharma Giant
The Motley Fool

Pfizer 's (PFE +1.84%) shares have significantly underperformed broader equities over the past three years. The company's reliance on its coronavirus portfolio has been a weakness, as vaccination rates have declined, while U.S. regulators have made…

marketbeat.com - Royalty Pharma (NASDAQ:RPRX) EVP Sells $5,652,000.00 in Stock
Royalty Pharma (NASDAQ:RPRX) EVP Sells $5,652,000.00 in Stock
MarketBeat

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Christopher Hite sold 100,000 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $56.52, for a total value of $5,652,000.00. Following…

forbes.com - Bruce Japsen - Peak Rock Capital Buys Asembia As Specialty Pharmacy Industry Grows
Peak Rock Capital Buys Asembia As Specialty Pharmacy Industry Grows
Forbes

The private equity firm Peak Rock Capital is buying Asembia, a fast-growing provider of services surrounding specialty pharmacy including distribution, group purchasing and technology connecting pharmacies, drug makers, patients and other…

marketbeat.com - Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,099 Shares
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 9,099 Shares
MarketBeat

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 9,099 shares of the business's stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $55.88, for a total value of $508,452.12. The…

abovethelaw.com - Kathryn Rubino - Medicine's Monopoly Problem
Medicine's Monopoly Problem
Above the Law

Tahir Amin started out wanting to play professional football in England. He found law instead, and specifically intellectual property law in the early 1990s, when the field was still new enough to feel cutting edge. After a decade of commercial IP…

globenewswire.com - GENFIT S.A. - GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
GlobeNewswire

Coverage and future reimbursement (effective August 10, 2026) secured for NASHnext, Labcorp's non-invasive blood-based diagnostic test powered by GENFIT's proprietary NIS4 technology Focuses on patients at highest risk, including those with…

indianexpress.com - Nitendra Pal Singh - UPSC Essentials | Daily subject-wise quiz : Economy MCQs on wage rates for unskilled manual workers under VB-G RAM G, Financial Stability Report and more (Week 169)
UPSC Essentials | Daily subject-wise quiz : Economy MCQs on wage rates for unskilled manual workers under VB-G RAM G, Financial Stability Report and more (Week 169)
The Indian Express

2. The state government can fix their wage rate for different parts of the state. 3. The wage rate notified under the VB G RAM G Act can be lower than the prevailing wage rate notified under Section 6 of the MGNREGA, 2005. How many of the…

seekingalpha.com - Albert Anthony - Rayonier: After Recent Merger, The Bet Is On Synergies And Land Value Appreciation (RYN)
Rayonier: After Recent Merger, The Bet Is On Synergies And Land Value Appreciation (RYN)
Seeking Alpha

Albert Anthony is the pen name of a business author on Amazon and his newest book is 'How To Pick Stocks: 8 Steps For Long-Term Investing with Fundamental & Technical Analysis,' now available as a 2026 edition paperback and Kindle ebook in several…

thehindubusinessline.com - BatX Energies raises ₹105 cr in funding round led by IvyCap Ventures
BatX Energies raises ₹105 cr in funding round led by IvyCap Ventures
BusinessLine

Battery recycling and critical minerals recovery firm BatX Energies on Thursday said it has raised ₹105 crore in a funding round led by IvyCap Ventures. The Series A funding round also saw the participation of existing investors Zephyr…

thenational.scot - Alasdair Ferguson - UK-US drug deal could result in 220,000 avoidable deaths in England, analysis finds
UK-US drug deal could result in 220,000 avoidable deaths in England, analysis finds
The National

The NHS in England will have to divert £45 billion from essential services to help pay for new medicines under the terms of the deal agreed between the UK Government and Donald Trump 's US administration last December. Ministers have been…

washingtonmonthly.com - Bill Scher - The Fight in the Democratic Party Is Not Left vs. Center, But Left vs. Left
The Fight in the Democratic Party Is Not Left vs. Center, But Left vs. Left
Washington Monthly

After 15-term Denver-area U.S. Representative Diana DeGette lost her Democratic primary to the 29-year-old Democratic Socialists of America member Melat Kiros, the socialist streamer Hasan Piker, drink in hand, crowed, “Thank you for not…

news-medical.net - Insilico Medicine partners with Takeda for AI-driven drug discovery
Insilico Medicine partners with Takeda for AI-driven drug discovery
News-Medical

Insilico Medicine ('Insilico' HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates…

Receive a Daily briefing on Pharma Industry News

Get Started